In a report released on February 19, Mike Kratky from Leerink Partners reiterated a Buy rating on Penumbra (PEN – Research Report), with a ...

Penumbra stock gapped up Wednesday after the medtech company beat fourth-quarter expectations, though its revenue guidance ...

Medical device company Penumbra (NYSE:PEN) will be reporting earnings tomorrow afternoon. Here’s what you need to know.

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has ...

Penumbra (NYSE:PEN – Free Report) had its price objective increased by Robert W. Baird from $305.00 to $328.00 in a report ...

Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the ...

Medical device company Penumbra (NYSE:PEN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up ...

Investors might want to bet on Penumbra (PEN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Penumbra (NYSE:PEN – Get Free Report) had its price target hoisted by equities research analysts at Truist Financial from $285.00 to $325.00 in a note issued to investors on Wednesday,Benzinga reports ...

If you want an excellent example of what makes Penumbra such a special company, check out its current production.

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the ...